Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of Empagliflozin to Treat Prediabetes - a Randomized, Double-blind, Placebo-controlled 13-week Intervention Trial

NCT05426525 is registered in ClinicalTrials.gov with Oregon State University as lead sponsor.

NCT NCT05426525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05426525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of Empagliflozin to Treat Prediabetes - a Randomized, Double-blind, Placebo-controlled 13-week Intervention Trial
Lead sponsor
Oregon State University
Phase
Phase 4
Overall status
Completed
Start date
October 13, 2022
Completion date
August 20, 2026
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

overweight and obesity, prediabetes, prediabetic state